AU2009260822B2 - Preparation and composition of Inter-alpha inhibitor proteins from blood - Google Patents

Preparation and composition of Inter-alpha inhibitor proteins from blood Download PDF

Info

Publication number
AU2009260822B2
AU2009260822B2 AU2009260822A AU2009260822A AU2009260822B2 AU 2009260822 B2 AU2009260822 B2 AU 2009260822B2 AU 2009260822 A AU2009260822 A AU 2009260822A AU 2009260822 A AU2009260822 A AU 2009260822A AU 2009260822 B2 AU2009260822 B2 AU 2009260822B2
Authority
AU
Australia
Prior art keywords
ialp
proteins
wash
icdp
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009260822A
Other languages
English (en)
Other versions
AU2009260822A1 (en
Inventor
Peter Brne
Yow-Pin Lim
Edward S. Sirya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothera Biologics Inc
Original Assignee
Prothera Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothera Biologics Inc filed Critical Prothera Biologics Inc
Publication of AU2009260822A1 publication Critical patent/AU2009260822A1/en
Application granted granted Critical
Publication of AU2009260822B2 publication Critical patent/AU2009260822B2/en
Assigned to PROTHERA BIOLOGICS, INC. reassignment PROTHERA BIOLOGICS, INC. Request to Amend Deed and Register Assignors: PRO THERA BIOLOGICS, LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2009260822A 2008-05-28 2009-05-28 Preparation and composition of Inter-alpha inhibitor proteins from blood Active AU2009260822B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13026908P 2008-05-28 2008-05-28
US61/130,269 2008-05-28
PCT/US2009/003291 WO2009154695A1 (en) 2008-05-28 2009-05-28 Preparation and composition of inter-alpha inhibitor proteins from blood

Publications (2)

Publication Number Publication Date
AU2009260822A1 AU2009260822A1 (en) 2009-12-23
AU2009260822B2 true AU2009260822B2 (en) 2016-09-22

Family

ID=41434346

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009260822A Active AU2009260822B2 (en) 2008-05-28 2009-05-28 Preparation and composition of Inter-alpha inhibitor proteins from blood

Country Status (13)

Country Link
US (3) US9139641B2 (enExample)
EP (1) EP2291654B1 (enExample)
JP (3) JP5793076B2 (enExample)
KR (3) KR101828433B1 (enExample)
CN (2) CN102112876B (enExample)
AU (1) AU2009260822B2 (enExample)
BR (2) BR122020017577B1 (enExample)
CA (1) CA2726281C (enExample)
DK (1) DK2291654T3 (enExample)
ES (1) ES2673005T3 (enExample)
PT (1) PT2291654T (enExample)
TR (1) TR201808152T4 (enExample)
WO (1) WO2009154695A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004289252C1 (en) 2003-11-08 2013-06-20 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use
AU2009260822B2 (en) 2008-05-28 2016-09-22 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from blood
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma
KR101443257B1 (ko) * 2011-10-18 2014-09-19 주식회사 종근당 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
EP3041857B1 (en) * 2013-09-04 2019-05-08 EMD Millipore Corporation Protein a chromatography
HUE057005T2 (hu) * 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
CN104138374A (zh) * 2014-07-26 2014-11-12 滨州医学院 硫酸阿扎那韦在制备预防或治疗内毒素血症和脓毒症的药物中的应用
WO2017066683A1 (en) * 2015-10-15 2017-04-20 Plasma Technologies, Llc Methods for extracting proteins from blood plasma
EP3512539A4 (en) 2016-09-13 2020-07-29 Prothera Biologics, Inc. METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
BR112019022358A2 (pt) * 2017-04-25 2020-05-19 Prothera Biologics Inc métodos para quantificar proteínas inibidoras inter-alfa
US11040068B2 (en) * 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
US11634680B2 (en) * 2017-11-20 2023-04-25 Lonza Ltd Process and system for propagating cell cultures while preventing lactate accumulation
EP3870147A4 (en) * 2018-10-24 2022-08-31 Prothera Biologics, Inc. INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF
CN109900689B (zh) * 2019-03-28 2021-12-10 复星诊断科技(长沙)有限公司 抗干扰膜及肝功能联合测试条
AU2021377336A1 (en) 2020-11-16 2023-07-06 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
WO2023089503A1 (en) * 2021-11-16 2023-05-25 Takeda Pharmaceutical Company Limited Inter-alpha inhibitor protein formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070297982A1 (en) * 2003-11-08 2007-12-27 Prothera Biologics Preparation And Composition Of Inter-Alpha Inhibitor Proteins From Human Plasma For Therapeutic Use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839298A (en) * 1986-02-14 1989-06-13 Akzo N.V. Virus inactivating diluents used in immunoassays
ATE100210T1 (de) 1988-11-01 1994-01-15 Sanol Arznei Schwarz Gmbh Lyophilisiertes mdm enthaltende zusammensetzung und verfahren zu deren herstellung.
GB8928501D0 (en) 1989-12-18 1990-02-21 Unilever Plc Reagents
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
JPH0953775A (ja) 1995-06-09 1997-02-25 Kubota Corp 埋設管路
US6313091B1 (en) * 1995-07-20 2001-11-06 New York University Pharmaceutical compositions containing TSG-6 for treating inflammatory diseases and cancer-related pathologies and method
AU5134799A (en) 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6489128B1 (en) 2000-01-24 2002-12-03 Rhode Island Hospital, A Lifespan Partner Methods for detecting cancer of the central nervous system
US6660482B1 (en) 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
WO2002030983A2 (de) 2000-10-13 2002-04-18 Octapharma Ag Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
CA2426102A1 (en) 2000-12-08 2002-08-01 Genentech, Inc. Method of diagnosing and treating cartilaginous disorders
GB0114709D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Stabilised formulations of amlodipine maleate
US20030027848A1 (en) 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
US20040009212A1 (en) * 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
KR20040098023A (ko) * 2002-03-26 2004-11-18 테바 파마슈티컬 인더스트리즈 리미티드 약물 미세입자
BRPI0408323A (pt) * 2003-03-14 2006-03-07 Nirmal Mulye processo para a preparação de compimidos de liberação prolongada
JP2007506681A (ja) 2003-09-23 2007-03-22 ピーディーエル バイオファーマ，インコーポレイティド 抗ｉｌ−２受容体抗体による呼吸器疾患の治療
PL1765866T3 (pl) 2004-06-07 2014-06-30 Therapure Biopharma Inc Wydzielanie białek osocza lub surowicy
US7939282B2 (en) 2004-10-21 2011-05-10 Rhode Island Hospital Methods for detecting sepsis
CN101160133B (zh) 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
CA2623940C (en) 2005-09-27 2017-01-10 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
WO2007076062A2 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2008067655A1 (en) 2006-12-05 2008-06-12 Q6 Biomaterials Inc. Biocompatible hydrogel-based scaffolds
AU2009260822B2 (en) 2008-05-28 2016-09-22 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from blood
EP2313106B1 (en) 2008-07-18 2016-03-30 A1M Pharma AB Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
AU2009325088B2 (en) 2008-12-10 2014-06-19 Duke University Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US9562906B2 (en) 2010-06-10 2017-02-07 National University Of Singapore Methods for detection of gastric cancer
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070297982A1 (en) * 2003-11-08 2007-12-27 Prothera Biologics Preparation And Composition Of Inter-Alpha Inhibitor Proteins From Human Plasma For Therapeutic Use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIM, Y.-P. et al., Journal of Chromatography A, 2005, vol. 1065, pages 39-43 *

Also Published As

Publication number Publication date
CA2726281A1 (en) 2009-12-23
KR101828433B1 (ko) 2018-03-29
US20110190194A1 (en) 2011-08-04
US20170157224A1 (en) 2017-06-08
PT2291654T (pt) 2018-06-15
US20160145318A1 (en) 2016-05-26
EP2291654A1 (en) 2011-03-09
JP2015155434A (ja) 2015-08-27
US10076559B2 (en) 2018-09-18
AU2009260822A1 (en) 2009-12-23
KR101714008B1 (ko) 2017-03-09
KR20160129914A (ko) 2016-11-09
DK2291654T3 (en) 2018-06-14
BR122020017577B1 (pt) 2021-10-26
KR20170116196A (ko) 2017-10-18
BRPI0913949A2 (pt) 2015-10-20
JP5793076B2 (ja) 2015-10-14
JP2018008941A (ja) 2018-01-18
CN102112876B (zh) 2017-12-08
EP2291654B1 (en) 2018-04-11
EP2291654A4 (en) 2011-08-24
US9139641B2 (en) 2015-09-22
KR20110053404A (ko) 2011-05-23
TR201808152T4 (tr) 2018-07-23
CN106928346B (zh) 2021-09-07
JP6309915B2 (ja) 2018-04-11
CA2726281C (en) 2023-04-18
CN106928346A (zh) 2017-07-07
ES2673005T3 (es) 2018-06-19
WO2009154695A1 (en) 2009-12-23
CN102112876A (zh) 2011-06-29
JP2011524343A (ja) 2011-09-01
US9758570B2 (en) 2017-09-12

Similar Documents

Publication Publication Date Title
US10076559B2 (en) Preparation and composition of inter-alpha inhibitor proteins from blood
USRE47972E1 (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
CN101160133B (zh) 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
HK1243715B (zh) 来自血液的间-α抑制物蛋白的制备和组合物
HK1243715A1 (en) Preparation and composition of inter-alpha inhibitor proteins from blood
CN103142650B (zh) 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
HK1230523A1 (en) Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
HK1121670B (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: PROTHERA BIOLOGICS, INC.

Free format text: FORMER NAME(S): PRO THERA BIOLOGICS, LLC